ASM 981 pimecrolimus: Phase II

In a double-blind, dose-ranging, placebo-controlled European Phase II trial of ASM 981 in 50 patients with chronic psoriasis, patients receiving 20 mg of ASM 981 twice daily had a 60 percent reduction...